Search

Your search keyword '"Mokhtari, K."' showing total 663 results
Start Over Author "Mokhtari, K."
663 results on '"Mokhtari, K."'

1. Prognosis of glioblastoma patients improves significantly over time interrogating historical controls

Author

Thomas-Joulié, A., Tran, S., El Houari, L., Seyve, A., Bielle, F., Birzu, C., Lozano-Sanchez, F., Mokhtari, K., Giry, M., Marie, Y., Laigle-Donadey, F., Dehais, C., Houillier, C., Psimaras, D., Alentorn, A., Laurenge, A., Touat, M., Sanson, M., Hoang-Xuan, K., Kas, A., Rozenblum, L., Habert, M.-O., Nichelli, L., Leclercq, D., Galanaud, D., Jacob, J., Karachi, C., Capelle, L., Carpentier, A., Mathon, B., Belin, L., and Idbaih, A.

Published
2024
Full Text
View/download PDF

9. Molecular and clinical diversity in primary central nervous system lymphoma

Author

Hernández-Verdin, I., Kirasic, E., Wienand, K., Mokhtari, K., Eimer, S., Loiseau, H., Rousseau, A., Paillassa, J., Ahle, G., Lerintiu, F., Uro-Coste, E., Oberic, L., Figarella-Branger, D., Chinot, O., Gauchotte, G., Taillandier, L., Marolleau, J.-P., Polivka, M., Adam, C., Ursu, R., Schmitt, A., Barillot, N., Nichelli, L., Lozano-Sánchez, F., Ibañez-Juliá, M.-J., Peyre, M., Mathon, B., Abada, Y., Charlotte, F., Davi, F., Stewart, C., de Reyniès, A., Choquet, S., Soussain, C., Houillier, C., Chapuy, B., Hoang-Xuan, K., Alentorn, A., Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), University Medical Center Göttingen (UMG), Freie Universität Berlin, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de pathologie [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, CHU Bordeaux [Bordeaux], Imagerie moléculaire et thérapies innovantes en oncologie (IMOTION), Université de Bordeaux (UB), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Service de Neurologie [Hôpitaux Civils de Colmar], Hôpitaux Civils Colmar, Hôpitaux Civils de Colmar, Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Amiens-Picardie, HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 (HEMATIM), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Université Paris Diderot - Paris 7 (UPD7), Hopital Saint-Louis [AP-HP] (AP-HP), Institut Bergonié [Bordeaux], UNICANCER, Sorbonne Université (SU), Centre Hospitalier Saint Jean de Perpignan, Broad Institute of MIT and Harvard (BROAD INSTITUTE), Harvard Medical School [Boston] (HMS)-Massachusetts Institute of Technology (MIT)-Massachusetts General Hospital [Boston], Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Institut Curie - Saint Cloud (ICSC), DESSAIVRE, Louise, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d’Anatomie Pathologique [CHRU Nancy], and École pratique des hautes études (EPHE)

Subjects
[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Oncology, tumor heterogeneity, Hematology, multi-omics, microenvironment, PCNSL, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Primary central nervous system lymphoma (PCNSL) is a rare and distinct entity within diffuse large B-cell lymphoma presenting with variable response rates probably to underlying molecular heterogeneity.To identify and characterize PCNSL heterogeneity and facilitate clinical translation, we carried out a comprehensive multi-omic analysis [whole-exome sequencing, RNA sequencing (RNA-seq), methylation sequencing, and clinical features] in a discovery cohort of 147 fresh-frozen (FF) immunocompetent PCNSLs and a validation cohort of formalin-fixed, paraffin-embedded (FFPE) 93 PCNSLs with RNA-seq and clinico-radiological data.Consensus clustering of multi-omic data uncovered concordant classification of four robust, non-overlapping, prognostically significant clusters (CS). The CS1 and CS2 groups presented an immune-cold hypermethylated profile but a distinct clinical behavior. The 'immune-hot' CS4 group, enriched with mutations increasing the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and nuclear factor-κB activity, had the most favorable clinical outcome, while the heterogeneous-immune CS3 group had the worse prognosis probably due to its association with meningeal infiltration and enriched HIST1H1E mutations. CS1 was characterized by high Polycomb repressive complex 2 activity and CDKN2A/B loss leading to higher proliferation activity. Integrated analysis on proposed targets suggests potential use of immune checkpoint inhibitors/JAK1 inhibitors for CS4, cyclin D-Cdk4,6 plus phosphoinositide 3-kinase (PI3K) inhibitors for CS1, lenalidomide/demethylating drugs for CS2, and enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) inhibitors for CS3. We developed an algorithm to identify the PCNSL subtypes using RNA-seq data from either FFPE or FF tissue.The integration of genome-wide data from multi-omic data revealed four molecular patterns in PCNSL with a distinctive prognostic impact that provides a basis for future clinical stratification and subtype-based targeted interventions.

Published
2023
Full Text
View/download PDF

10. Guidelines, “minimal requirements” and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean arEa) Neuro-Oncology working party

Author

Belkacemi, Y., Bolle, S., Bourdeaut, F., Collin, P., Cornu, P., Delatre, J.-Y., Dhermain, F., Doz, F., Habrand, J.-L., Hoang-Xuan, K., Idbaih, A., Mammar, H., Martin-Duverneuil, N., Mokhtari, K., Roujeau, T., Acharqui, A., Atit Benali, S., Bakhti, S., Bena, F., Bendjaafar, N., Benider, A., Bouaouina, N., Bounedjar, A., Boussen, H., Bouyoucef, K., Bouzid, K., Chougai, Z., Daoud, J., Errihani, H., Essoudaigui, F., Gachi, F., Harif, M., Hilmani, S., Hsissen, L., Idali, B., Karkouri, M., Kerboua, E., Ouahabi, A., Sahraoui, S., Sadki, O., Sami, A., Samlali, R, and Terkmani, F.

Published
2016
Full Text
View/download PDF

12. OS07.1.A A threshold of mitotic activity and post-surgery residual volume are independant prognostic factors in astrocytoma IDH-mutant

Author

Tran, S, primary, Thomas, A, additional, Touat, M, additional, Karachi, C, additional, Lozano, F, additional, Mokhtari, K, additional, Dehais, C, additional, Feuvret, L, additional, Carpentier, C, additional, Giry, M, additional, Doukani, H, additional, Lerond, J, additional, Marie, Y, additional, Sanson, M, additional, Idbaih, A, additional, Carpentier, A, additional, Hoang-Xuan, K, additional, Capelle, L, additional, and Bielle, F, additional

Published
2022
Full Text
View/download PDF

16. Pan-cancer landscape of AID-related mutations, composite mutations, and their potential role in the ICI response

Author

Hernández-Verdin, I, Akdemir, K, Ramazzotti, D, Caravagna, G, Labreche, K, Mokhtari, K, Hoang-Xuan, K, Peyre, M, Bielle, F, Touat, M, Idbaih, A, Duval, A, Sanson, M, Alentorn, A, Isaias Hernández-Verdin, Kadir C. Akdemir, Daniele Ramazzotti, Giulio Caravagna, Karim Labreche, Karima Mokhtari, Khê Hoang-Xuan, Matthieu Peyre, Franck Bielle, Mehdi Touat, Ahmed Idbaih, Alex Duval, Marc Sanson, Agustí Alentorn, Hernández-Verdin, I, Akdemir, K, Ramazzotti, D, Caravagna, G, Labreche, K, Mokhtari, K, Hoang-Xuan, K, Peyre, M, Bielle, F, Touat, M, Idbaih, A, Duval, A, Sanson, M, Alentorn, A, Isaias Hernández-Verdin, Kadir C. Akdemir, Daniele Ramazzotti, Giulio Caravagna, Karim Labreche, Karima Mokhtari, Khê Hoang-Xuan, Matthieu Peyre, Franck Bielle, Mehdi Touat, Ahmed Idbaih, Alex Duval, Marc Sanson, and Agustí Alentorn

Abstract

Activation-induced cytidine deaminase, AICDA or AID, is a driver of somatic hypermutation and class-switch recombination in immunoglobulins. In addition, this deaminase belonging to the APOBEC family may have off-target effects genome-wide, but its effects at pan-cancer level are not well elucidated. Here, we used different pan-cancer datasets, totaling more than 50,000 samples analyzed by whole-genome, whole-exome, or targeted sequencing. AID mutations are present at pan-cancer level with higher frequency in hematological cancers and higher presence at transcriptionally active TAD domains. AID synergizes initial hotspot mutations by a second composite mutation. AID mutational load was found to be independently associated with a favorable outcome in immune-checkpoint inhibitors (ICI) treated patients across cancers after analyzing 2000 samples. Finally, we found that AID-related neoepitopes, resulting from mutations at more frequent hotspots if compared to other mutational signatures, enhance CXCL13/CCR5 expression, immunogenicity, and T-cell exhaustion, which may increase ICI sensitivity.

Published
2022

18. Differences in the Metacognitive Awareness of Reading Strategies among Native and Non-Native Readers.

Author

Sheorey, R. and Mokhtari, K.

Abstract

Examines the differences in the reported use of reading strategies of native and non-native English speakers when reading academic materials. Participants were native English speaking and English-as-a-Second-Language college students who completed a survey of reading strategies aimed at discerning the strategies readers report using when coping with academic reading tasks. (Author/VWL)

Published
2001

22. OC-0077 High-dose post-operative Protontherapy to improve the outcome of high-grade meningiomas

Author

Holub, K., primary, Froelich, S., additional, Adle-Biassette, H., additional, Guichard, J., additional, Champeaux, K., additional, Carpentier, A., additional, Mokhtari, K., additional, Feuvret, L., additional, Lot, G., additional, Bolle, S., additional, Alapetite, C., additional, Helfre, S., additional, Goudjil, F., additional, Pasquie, I., additional, Nauraye, C., additional, El Ayachy, R., additional, Calugaru, V., additional, Dendale, R., additional, and Mammar, H., additional

Published
2021
Full Text
View/download PDF

25. Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study

Author

Li, BK, Vasiljevic, A, Dufour, C, Yao, F, Ho, BLB, Lu, M, Hwang, EI, Gururangan, S, Hansford, JR, Fouladi, M, Nobusawa, S, Laquerriere, A, Delisle, M-B, Fangusaro, J, Forest, F, Toledano, H, Solano-Paez, P, Leary, S, Birks, D, Hoffman, LM, Szathmari, A, Faure-Conter, C, Fan, X, Catchpoole, D, Zhou, L, Schultz, KAP, Ichimura, K, Gauchotte, G, Jabado, N, Jones, C, Loussouarn, D, Mokhtari, K, Rousseau, A, Ziegler, DS, Tanaka, S, Pomeroy, SL, Gajjar, A, Ramaswamy, V, Hawkins, C, Grundy, RG, Hill, DA, Bouffet, E, Huang, A, Jouvet, A, Li, BK, Vasiljevic, A, Dufour, C, Yao, F, Ho, BLB, Lu, M, Hwang, EI, Gururangan, S, Hansford, JR, Fouladi, M, Nobusawa, S, Laquerriere, A, Delisle, M-B, Fangusaro, J, Forest, F, Toledano, H, Solano-Paez, P, Leary, S, Birks, D, Hoffman, LM, Szathmari, A, Faure-Conter, C, Fan, X, Catchpoole, D, Zhou, L, Schultz, KAP, Ichimura, K, Gauchotte, G, Jabado, N, Jones, C, Loussouarn, D, Mokhtari, K, Rousseau, A, Ziegler, DS, Tanaka, S, Pomeroy, SL, Gajjar, A, Ramaswamy, V, Hawkins, C, Grundy, RG, Hill, DA, Bouffet, E, Huang, A, and Jouvet, A

Abstract

Pineoblastomas (PBs) are rare, aggressive pediatric brain tumors of the pineal gland with modest overall survival despite intensive therapy. We sought to define the clinical and molecular spectra of PB to inform new treatment approaches for this orphan cancer. Tumor, blood, and clinical data from 91 patients with PB or supratentorial primitive neuroectodermal tumor (sPNETs/CNS-PNETs), and 2 pineal parenchymal tumors of intermediate differentiation (PPTIDs) were collected from 29 centres in the Rare Brain Tumor Consortium. We used global DNA methylation profiling to define a core group of PB from 72/93 cases, which were delineated into five molecular sub-groups. Copy number, whole exome and targeted sequencing, and miRNA expression analyses were used to evaluate the clinico-pathologic significance of each sub-group. Tumors designated as group 1 and 2 almost exclusively exhibited deleterious homozygous loss-of-function alterations in miRNA biogenesis genes (DICER1, DROSHA, and DGCR8) in 62 and 100% of group 1 and 2 tumors, respectively. Recurrent alterations of the oncogenic MYC-miR-17/92-RB1 pathway were observed in the RB and MYC sub-group, respectively, characterized by RB1 loss with gain of miR-17/92, and recurrent gain or amplification of MYC. PB sub-groups exhibited distinct clinical features: group 1-3 arose in older children (median ages 5.2-14.0 years) and had intermediate to excellent survival (5-year OS of 68.0-100%), while Group RB and MYC PB patients were much younger (median age 1.3-1.4 years) with dismal survival (5-year OS 37.5% and 28.6%, respectively). We identified age < 3 years at diagnosis, metastatic disease, omission of upfront radiation, and chr 16q loss as significant negative prognostic factors across all PBs. Our findings demonstrate that PB exhibits substantial molecular heterogeneity with sub-group-associated clinical phenotypes and survival. In addition to revealing novel biology and therapeutics, molecular sub-grouping of PB can be explo

Published
2020

26. MRI features of intra-axial histiocytic brain mass lesions

Author

Luna, L.P., primary, Drier, A., additional, Aygun, N., additional, Mokhtari, K., additional, Hoang-Xuan, K., additional, Galanaud, D., additional, Donadieu, J., additional, Dormont, D., additional, Haroche, J., additional, and Martin-Duverneuil, N., additional

Published
2021
Full Text
View/download PDF

35. Prognostic significance of NAB2-STAT6 fusion variants and TERT promotor mutations in solitary fibrous tumors/hemangiopericytomas of the CNS: not (yet) clear

Author

Vogels, R, Macagno, N, Griewank, K, Groenen, P, Verdijk, M, Fonville, J, Kusters, B, Figarella-Branger, D, Wesseling, P, Bouvier, C, Flucke, U, Cornu, P, Dufour, H, Guyotat, J, Jouvet, A, Metellus, P, Mokhtari, K, Vasiljevic, A, Varlet, P, Bekers, E, Djafarihamedani, M, Kurt, E, Kusters-Vandevelde, H, Fleischeuer, R, Leenstra, Sieger, Robe, P, Spliet, W, Troost, D, van Furth, W, Radboud University Medical Center [Nijmegen], Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Service de Neuropathologie [AP-HM Hôpital de la Timone], Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM), Marseille medical genetics - Centre de génétique médicale de Marseille (MMG), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), University Hospital Essen, Stichting PAMM, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], Service d’Anatomie Pathologique et de Neuropathologie, APHM, Hôpital de la Timone, Hôpital de la Timone [CHU - APHM] (TIMONE), Aix Marseille Université (AMU), VU University Medical Center [Amsterdam], AUTRES, Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Pathology, CCA - Imaging and biomarkers, and Neurosurgery

Subjects
Solitary fibrous tumor, Medizin, Clinical Neurology, Nab2 stat6, Biology, Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9], medicine.disease_cause, Pathology and Forensic Medicine, Central Nervous System Neoplasms, 03 medical and health sciences, Cellular and Molecular Neuroscience, 0302 clinical medicine, medicine, Humans, Oncogene Fusion, Promoter Regions, Genetic, Telomerase, Retrospective Studies, 030304 developmental biology, 0303 health sciences, Mutation, [SDV.GEN]Life Sciences [q-bio]/Genetics, Promoter, Prognosis, medicine.disease, Disorders of movement Donders Center for Medical Neuroscience [Radboudumc 3], Progression-Free Survival, 3. Good health, Clinical neurology, Repressor Proteins, Survival Rate, Solitary Fibrous Tumors, 030220 oncology & carcinogenesis, Cancer research, Neurology (clinical), STAT6 Transcription Factor, Hemangiopericytoma
Abstract

International audience; Grading of meningeal solitary fibrous tumors/hemangiopericytomas(SFTs/HPCs) of the central nervous system (CNS)is nowadays based on histologic criteria as described in therevised fourth edition of the WHO Classification of CNStumors [10] or the more recently published, updated versionof the Marseille Grading System (MGS) [11]. Histologybasedgrading of CNS SFTs/HPCs allows for discriminatingsubgroups with significant differences in prognosis. However,the often-piecemealresection of these tumors mayhamper adequate evaluation of mitotic activity and necrosis,and thereby assessment of malignancy grade. NAB2–STAT6fusion is the molecular hallmark of both soft tissue SFTs andCNS SFTs/HPCs, and the resultingfusion protein accumulatesin the nucleus and acts as a transcriptional activatorof early growth response mediated pathways with STAT6immunohistochemistry being a very sensitive and specifictool for their diagnosis [5, 8, 12, 14]. For soft tissue SFTs,particular NAB2–STAT6 fusion variants as well as telomerasereverse transcriptase (TERT) promoter mutations leadingto telomerase activity and tumor cell immortalization havebeen reported to have prognostic value. Some studies haveincluded CNS SFTs/HPCs in their cohort, but because ofsmall numbers and lack of (long term) follow-up data theprognostic value of these markers for CNS SFTs/HPCs isstill unclear.

Published
2019
Full Text
View/download PDF

37. Grading of meningeal solitary fibrous tumors/hemangiopericytomas: analysis of the prognostic value of the Marseille Grading System in a cohort of 132 patients

Author

Macagno, N., Vogels, R.J.C., Appay, R., Colin, C., Mokhtari, K., Kurt, E., Kusters, B., Wesseling, P., Figarella-Branger, D., Flucke, U.E., Bouvier, C., Macagno, N., Vogels, R.J.C., Appay, R., Colin, C., Mokhtari, K., Kurt, E., Kusters, B., Wesseling, P., Figarella-Branger, D., Flucke, U.E., and Bouvier, C.

Abstract

Item does not contain fulltext, The finding that meningeal solitary fibrous tumors (SFTs) and meningeal hemangiopericytomas (HPCs) are both characterized by NAB2-STAT6 gene fusion has pushed their inclusion in the WHO 2016 Classification of tumors of the central nervous system (CNS) as different manifestations of the same entity. Given that the clinical behavior of the CNS SFT/HPC spectrum ranges from benign to malignant, it is presently unclear whether the grading criteria are still adequate. Here, we present the results of a study that analyzed the prognostic value of an updated version of the Marseille Grading System (MGS) in a retrospectively assembled cohort of 132 primary meningeal SFTs/HPCs with nuclear overexpression of STAT6. The median patient follow-up was 64 months (range 4-274 months); 73 cases (55%) were MGS I, 50 cases (38%) MGS II and 9 cases (7%) were MGS III. Progression-free survival (PFS) and disease-specific survival (DSS) were investigated using univariate analysis: the prognostic factors for PFS included MGS, extent of surgery, radiotherapy, chemotherapy and mitotic activity >/=5/10 high-power field (HPF). Moreover, MGS, radiotherapy, mitotic activity >/=5/10 HPF, and necrosis were the prognostic factors measured for DSS. In multivariate analysis, extent of surgery, mitotic activity >/=5/10 HPF, MGS I and MGS III were the independent prognostic factors measured for PFS while necrosis, MGS III and radiotherapy were the independent prognostic factors for DSS. In conclusion, our results show that assessing the malignancy risk of SFT/HPC should not rely on one single criterion like mitotic activity. Therefore, MGS is useful as it combines the value of different criteria. In particular, the combination of a high mitotic activity and necrosis (MGS III) indicates a particularly poor prognosis.

Published
2019

39. Effects of Achillea tenuifolia Lam. hydro-alcoholic extract on anxiety-like behavior and reproductive parameters in rat model of chronic restraint stress.

Author

Bagheri, Y, Fathi, E, Maghoul, A, Moshtagh, S, Mokhtari, K, Abdollahpour, A, Montazersaheb, S, and Bagheri, A

Subjects
PSYCHOLOGICAL stress, IMMOBILIZATION stress, ANIMAL disease models, ANIMAL sexual behavior, ANXIETY, LABORATORY rats, SEMEN analysis, MALE reproductive organs
Abstract

Introduction: Achillea tenuifolia Lam (AT) has several biological activities and medicinal properties. In this study, we elucidated the impact of the AT on anxiety-related behaviors, reproductive parameters, antioxidant capacity in male rats subjected to chronic restraint stress (CRS). Methods: 35 Wistar rats were divided into five groups: control, CRS-control (received normal saline) and three CRS-treated groups received AT extract (100, 150, and 200 mg/kg body weight) for 21 consequences days. To induce CRS rats, the rats were immobilized for 21 days and received the extract orally. On the last day of treatment, anxiety-related behaviors were assessed through the sucrose preference test (SPT) as well as elevated plus maze (EPM) tests. Corticosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), testosterone levels were evaluated to determine reproductive capacity. Sperm parameters including the total count, motility, and viability were also analyzed. Weight of body, testis and seminal vesicles was measured as well. Results: The findings revealed that 100, 150, and 200 mg/kg of AT extract had anxiolytic effects in CRS rats, as confirmed by the EPM test and SPT. In addition, AT extract could improve fertile capacity and sperm quality to varying degrees. The level of corticosterone had decreased, whereas the level of LH, FSH and testosterone had increased in CRS-treated rats. Moreover, the reduced level of MDA coincided with an increased rate of antioxidant capacity. Our findings suggest that AT extract could alleviate stress-induced dysfunctions. Conclusion: Overall, these observations would infer that AT extract could improve fertility capacity and behavioral impairment in the stress conditions. Assumption pathway describing the probability underlying mechanism of CRS-induced anxiety and reproductive toxicity and protective effect of AT. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

43. OS9.3 Clinical, molecular and radiomic profile of gliomas with FGFR3-TACC3 fusion

Author

Picca, A, primary, Alentorn, A, additional, Saragoussi, E, additional, Bielle, F, additional, Ducray, F, additional, Villa, C, additional, Schmitt, Y, additional, Lerond, J, additional, Leclerc, J, additional, Lasorella, A, additional, Iavarone, A, additional, Mokhtari, K, additional, Savatovsky, J, additional, Sanson, M, additional, and Di Stefano, A, additional

Published
2019
Full Text
View/download PDF

44. P14.87 Leptomeningeal dissemination in high grade glioma: Correlation of MRI, cytology and standard CSF indices

Author

Durand, H, primary, Lamy, F, additional, Parratte, T, additional, Brinet, A, additional, Blain, A, additional, Gaultier, C, additional, Droy-Dupré, L, additional, Leblanc, S, additional, Oesterlé, H, additional, Olteanu, S, additional, Atlani, D, additional, Voirin, J, additional, Mokhtari, K, additional, and Ahle, G, additional

Published
2019
Full Text
View/download PDF

46. OS9.1 Clinical significance of hypermutation in gliomas

Author

Touat, M, primary, Li, Y, additional, Boynton, A, additional, Spurr, L, additional, Iorglescu, B, additional, Geduldig, J, additional, Birzu, C, additional, Lim Fat, M, additional, Santagata, S, additional, Coulet, F, additional, Beuvon, F, additional, Mokhtari, K, additional, Giry, M, additional, Block, S, additional, Guillerm, E, additional, Carpentier, A, additional, Huang, R, additional, Delattre, J, additional, Hoang-Xuan, K, additional, Sanson, M, additional, Duval, A, additional, Cherniack, A, additional, Reardon, D, additional, Wen, P, additional, Idbaih, A, additional, Marabelle, A, additional, Bandopadhayay, P, additional, Beroukhim, R, additional, Bielle, F, additional, and Ligon, K, additional

Published
2019
Full Text
View/download PDF

48. OS9.2 Radiomics analysis of lower-grade gliomas, a POLA Network study

Author

Younan, N, primary, Douzane, H, additional, Duran-Pena, A, additional, Nichelli, L, additional, Garcilazo, Y, additional, Dehais, C, additional, Ducray, F, additional, Carpentier, C, additional, Mokhtari, K, additional, Figarella-Branger, D, additional, Delattre, J, additional, Idbaih, A, additional, and Alentorn, A, additional

Published
2019
Full Text
View/download PDF

50. La biopsie cérébrale en médecine interne : un acte sûr et rentable

Author

Le Joncour, A., primary, Pineton De Chambrun, M., additional, Mokhtari, K., additional, Delattre, J.Y., additional, Leblond, V., additional, Caumes, E., additional, Cacoub, P., additional, Benveniste, O., additional, Cohen-Aubart, F., additional, Amoura, Z., additional, Amelot, A., additional, and Mathon, B., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results